APPARATUS FOR PLATELET FUNCTION TEST USING SPECKLE DECORRELATION TIME ANALYSIS

Abstract

The present invention relates to an apparatus for a platelet function test using speckle decorrelation time analysis. An apparatus for a platelet function test according to an exemplary embodiment of the present invention may include: a laser unit for irradiating a blood sample including platelets with a laser; an image capturing unit for obtaining a speckle image of the blood sample irradiated with the laser; and a control unit for determining the speckle decorrelation time for platelets.

Claims

1. An apparatus for a platelet function test, comprising: a laser unit for irradiating a blood sample comprising platelets with a laser; an image capturing unit for obtaining a speckle image of the blood sample irradiated with the laser; and a control unit for determining the speckle decorrelation time for platelets.

2. The apparatus of claim 1, further comprising a microfluidic chip for moving the blood sample, wherein the laser unit irradiates the blood sample moving through the microfluidic chip with a laser.

3. The apparatus of claim 2, wherein the microfluidic chip comprises an injection unit into which the blood sample is injected, a movement channel through which the injected blood sample moves, and a discharge unit through which the moved blood sample is discharged.

4. The apparatus of claim 3, further comprising a vacuum unit which is coupled to the microfluidic chip to move the blood sample by vacuum pressure.

5. The apparatus of claim 4, wherein the vacuum unit comprises a movement tube through which the discharged blood sample moves, a first valve which is coupled to the movement tube to open and close a flow of the blood sample, and a vacuum pump which is coupled to the movement tube to form a vacuum state inside the movement tube according to the opening and closing of the first valve.

6. The apparatus of claim 5, wherein the vacuum unit further comprises a buffer unit which is coupled to the movement tube to buffer the movement of the blood sample.

7. The apparatus of claim 5, wherein the vacuum pump forms a vacuum state inside the movement tube after the first valve is closed, the first valve is opened after the vacuum state inside the movement tube is formed, and the movement tube moves the blood sample based on vacuum pressure generated as the first valve is opened.

8. The apparatus of claim 1, wherein the control unit measures the function of platelets based on the speckle decorrelation time for platelets.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The above and other objects, features and advantages of the present invention will become more apparent to those of ordinary skill in the art by describing in detail exemplary embodiments thereof with reference to the accompanying drawings, in which:

[0023] FIG. 1A is a view illustrating the functional configuration of an apparatus for a platelet function test according to an exemplary embodiment of the present invention;

[0024] FIG. 1B is a view illustrating a microfluidic chip according to an exemplary embodiment of the present invention;

[0025] FIG. 2 is a view illustrating a set of speckle images according to an exemplary embodiment of the present invention;

[0026] FIG. 3A is a view illustrating a speckle decorrelation time graph for flow rate according to an exemplary embodiment of the present invention;

[0027] FIG. 3B is a view illustrating a speckle decorrelation time graph for particle size according to an exemplary embodiment of the present invention;

[0028] FIG. 3C is a view illustrating a speckle decorrelation time graph for particle concentration according to an exemplary embodiment of the present invention;

[0029] FIG. 4 is a view illustrating a speckle decorrelation time graph for the presence and absence of platelets according to an exemplary embodiment of the present invention;

[0030] FIGS. 5A and 5B are views illustrating a speckle decorrelation time graph for the presence and absence of platelets according to an exemplary embodiment of the present invention;

[0031] FIG. 6A to 6E are views illustrating a speckle decorrelation time graph for various platelet activation materials according to an exemplary embodiment of the present invention; and

[0032] FIG. 7A to 7D are views illustrating a light transmittance graph according to an exemplary embodiment of the present invention.

DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

[0033] Since the present invention may be modified into various forms and include various exemplary embodiments, specific exemplary embodiments will be illustrated in the drawings and described in detail.

[0034] Various features of the invention disclosed in the claims can be better understood in view of the drawings and the detailed description. Apparatuses, methods, manufacturing methods, and various embodiments disclosed herein are provided for the purpose of illustration. The disclosed structural and functional features are intended to enable those skilled in the art to specifically practice various embodiments, and are not intended to limit the scope of the invention. The disclosed terms and sentences are intended to explain various features of the disclosed invention in an easy-to-understand manner and are not intended to limit the scope of the invention.

[0035] In the description of the present invention, when it is determined that the detailed description for the related known technology can unnecessarily obscure the gist of the present invention, the detailed description thereof will be omitted.

[0036] Hereinafter, an apparatus for a platelet function test using speckle decorrelation time analysis according to an exemplary embodiment of the present invention will be described.

[0037] FIG. 1A is a view illustrating the functional configuration of an apparatus 100 for a platelet function test according to an exemplary embodiment of the present invention. FIG. 1B is a view illustrating a microfluidic chip 120 according to an exemplary embodiment of the present invention. FIG. 2 is a view illustrating a set of speckle images according to an exemplary embodiment of the present invention.

[0038] Referring to FIGS. 1A and 1B, an apparatus 100 for a platelet function test may include a laser unit 110, a microfluidic chip 120, a vacuum unit 130, an image capturing unit 140, and a control unit (not shown).

[0039] The laser unit 110 may irradiate a blood sample including platelets with a laser. In an exemplary embodiment, the microfluidic chip 120 may move the blood sample. In this case, the laser unit 110 may irradiate the blood sample moving through the microfluidic chip 120 with a laser.

[0040] In an exemplary embodiment, the microfluidic chip 120 may include an injection unit 122 into which a blood sample is injected, a movement channel 124 through which the injected blood sample moves, and a discharge unit 126 through which the moved blood sample is discharged.

[0041] The vacuum unit 130 may be coupled to the microfluidic chip 120 to move the blood sample by vacuum pressure.

[0042] In an exemplary embodiment, the vacuum unit 130 may include a movement tube 132 through which the discharged blood sample moves, a first valve 134 which is coupled to the movement tube 132 to open and close a flow of the blood sample, and a vacuum pump 136 which is coupled to the movement tube 132 to form a vacuum state inside the movement tube 132 according to the opening and closing of the first valve 134. For example, the first valve 134 may include a solenoid valve.

[0043] In an exemplary embodiment, the vacuum pump 136 may form a vacuum state inside the movement tube 132 after the first valve 134 is closed. For example, the vacuum pump 136 may include a syringe pump.

[0044] The first valve 134 may be opened after a vacuum state is formed inside the movement tube 132. Thus, the movement tube 132 may move a blood sample based on vacuum pressure generated as the first valve 134 is opened.

[0045] In an exemplary embodiment, the vacuum unit 130 may further include a buffer unit 138 which is coupled to the movement tube 132 to buffer the movement of the blood sample. In this case, the buffer unit 138 may be coupled to the movement tube 132 via a second valve. For example, the second valve may include a 3-way valve. The buffer unit 138 may include a vessel formed as an empty space.

[0046] The image capturing unit 140 may obtain a speckle image of the blood sample irradiated with the laser. In this case, the speckle image may include a speckle pattern which is irregularly generated by interference occurring when the laser is reflected by or passes through the blood sample.

[0047] In an exemplary embodiment, the image capturing unit 140 may include at least one of a lens onto which the laser emitted into the blood sample is projected, an iris, a polarizing plate and a camera.

[0048] The control unit may determine a speckle decorrelation time for platelets from the speckle image.

[0049] In an exemplary embodiment, the control unit may measure the function of platelets based on the speckle decorrelation time for platelets.

[0050] FIG. 2 is a view illustrating a set of speckle images according to an exemplary embodiment of the present invention.

[0051] Referring to FIG. 2, the speckle image may include a speckle pattern which is irregularly generated by interference occurring when the laser is reflected by or passes through the blood sample.

[0052] The speckle image may be obtained by the image capturing unit 140 at each specific cycle. In this case, the speckle decorrelation time may change the rate of deformation of the speckle pattern.

[0053] In an exemplary embodiment, the speckle decorrelation time may be determined based on the following <Equation 1>.

[00001]$\begin{array}{cc}{g}_2\left(\tau \right)=\frac{<I\left(t_0\right)I\left(t_0+\tau \right)>}{<I\left(t_0\right)><I\left(t_0+\tau \right)>}& \left[\mathrm{Equation}1\right]\end{array}$

[0054] Here, g.sub.2(τ) indicates an intensity autocorrelation function, I(t.sub.0) and I(t.sub.0+τ) indicates an intensity at each time, and < > indicates the average calculation of all the captured data.

[0055] In an exemplary embodiment, <Equation 1> may be associated with a field autocorrelation function and may be represented by the following <Equation 2>.

g.sub.2(τ)=1+β|g.sub.1(τ)|.sup.2  [Equation 2]

[0056] Here g.sub.2(τ) indicates an intensity autocorrelation function, g.sub.1(τ) indicates an electrical field autocorrelation function, and β indicates an experimental factor between 0 and 1, which is determined by the collection optics and the capture parameter (β=g.sub.2(o)−1).

[0057] In this case, the autocorrelation function may be produced by an electrical signal g.sub.1(τ) or a change in intensity g.sub.2(τ).

[0058] In an exemplary embodiment, the electrical field autocorrelation function g.sub.1(τ) may be represented by the following <Equation 3>.

[00002]$\begin{array}{cc}{g}_1\left(\tau \right)={\int }_0^{\infty }P\left(s\right)\exp \left[\left(-\frac{2\tau }{{\tau }_0}\right)\frac{s}{l^{*}}\right]\mathrm{ds}& \left[\mathrm{Equation}3\right]\end{array}$

[0059] Here, τ indicates decay time, τ.sub.0=1/Dk.sub.0.sup.2, k.sub.0(wavenumber)=2π/λ, D indicates the diffusion coefficient, l.sup.+ indicates the transport mean-free path, s indicates the path length, and P(s) indicates the distribution of the path length.

[0060] In an exemplary embodiment, the electrical field autocorrelations g.sub.1(τ) may be represented by the following <Equation 4>.

[00003]$\begin{array}{cc}{g}_1\left(\tau \right)={\int }_0^{\infty }P\left(s\right)\exp \left[-2\left[\tau /{\tau }_B+{\left(\tau /{\tau }_s\right)}^2\right]\frac{s}{l^{*}}\right]\mathrm{ds}& \left[\mathrm{Equation}4\right]\end{array}$

[0061] Here, τ.sub.B indicates the relaxation rate from the Brownian motion, and τ.sub.s indicates the relaxation rate from a laminar flow. That is, it can be confirmed that flow is not considered in <Equation 3>, and flow is considered in <Equation 4>.

[00004]$\begin{array}{cc}{g}_1\left(\tau \right)={\int }_0^{\infty }\exp \left[\frac{\tau }{\eta r}+{\left(\frac{\Gamma }{\tau \sqrt{30}}\right)}^2\right]\mathrm{ds}& \left[\mathrm{Equation}5\right]\end{array}$

[0062] That is, it can be confirmed through <Equation 5> that the electrical field autocorrelation function g.sub.1(τ) decays faster by the shear flow (Γ), the decrease in concentration (η) and the increase in particle size (r). In other words, the change in speckle decorrelation time may be determined by flow rate, concentration, and particle size.

[0063] FIG. 3A is a view illustrating a speckle decorrelation time graph for the flow rate according to an exemplary embodiment of the present invention. FIG. 3B is a view illustrating a speckle decorrelation time graph for particle size according to an exemplary embodiment of the present invention. FIG. 3C is a view illustrating a speckle decorrelation time graph for particle concentration according to an exemplary embodiment of the present invention.

[0064] Referring to FIG. 3A, as a result of confirming the cases where the flow rate (Q) is 20 μl/min (1.83 ms), 10 μl/min (1.94 ms), and 1 μl/min (2.16 ms), it can be confirmed that as the flow rate is increased, the speckle decorrelation time is decreased.

[0065] Referring to FIG. 3B, as a result of confirming the cases where the particle size (r) is 0.1 μm (1.76 ms), 1 μm (1.83 ms), and 10 μm (1.91 ms), it can be confirmed that as the particle size is increased, the speckle decorrelation time is also increased.

[0066] Referring to FIG. 3C, as a result of confirming the cases where the concentration variation (η) is 10% (1.76 ms), 20% (1.89 ms), and 50% (2.19 ms), it can be confirmed that as the concentration variation is increased, the speckle decorrelation time is also increased.

[0067] FIG. 4 is a view illustrating a speckle decorrelation time graph for the presence and absence of platelets according to an exemplary embodiment of the present invention.

[0068] Referring to FIG. 4, it can be confirmed that in the case of whole blood containing platelets in the movement tube 132, erythrocytes move in a tumbling motion. In contrast, it can be confirmed that in the case of platelet-poor blood in the movement tube 132, erythrocytes move in a random motion.

[0069] Thus, each speckle image for whole blood containing platelets and platelet-poor blood may be obtained at each time and analyzed in real time.

[0070] In this case, it can be confirmed that whole blood containing platelets has a longer speckle decorrelation time (τ) than platelet-poor blood, which is because there is a lower blood velocity due to platelet activation and also a slower change in speckle pattern.

[0071] FIGS. 5A and 5B are views illustrating a speckle decorrelation time graph for the presence and absence of platelets according to an exemplary embodiment of the present invention.

[0072] Referring to FIGS. 5A and 5B, it can be confirmed that whole blood containing platelets has a longer speckle decorrelation time compared to platelet-poor blood.

[0073] FIG. 6A to 6E are views illustrating a speckle decorrelation time graph for various platelet activation materials according to an exemplary embodiment of the present invention.

[0074] Referring to FIGS. 6A to 6E, a speckle decorrelation time test may be performed by utilizing a drug which activates platelets. In this case, it can be confirmed that the ADP platelet activator shows an approximate 5-fold or more difference between normal blood and abnormal blood. That is, the difference between normal and abnormal blood can be more clearly distinguished by utilizing a drug which activates platelets.

[0075] FIG. 7A to 7D are views illustrating a light transmittance graph according to an exemplary embodiment of the present invention.

[0076] Referring to FIGS. 7A to 7D, it can be confirmed that transmittance of light can also be measured, and a tendency similar to the speckle decorrelation time result is exhibited. Even in this case, the difference between normal and abnormal blood can be more clearly distinguished by utilizing the drug which activates platelets.

[0077] That is, according to various exemplary embodiments of the present invention, by collecting a small amount of blood and shortening a processing time, fast platelet diagnosis can be performed, antiplatelet drug resistance tests (for example, aspirin, clopidogrel) can be measured, so that synergistic effects can be obtained.

[0078] Further, according to various exemplary embodiments of the present invention, by analyzing the difference in the time when a speckle changes, the test time can be shortened using a system which has relatively high precision during the platelet test, has a low operation cost due to the configuration of a microfluidic chip and a simple system, and is capable of performing measurement in a short period of time. For example, the test may be performed in a required time of less than 1 minute using a blood volume of less than 10 μl.

[0079] According to an exemplary embodiment of the present invention, by analyzing the difference in the time when a speckle changes, the test time can be shortened using a system which has relatively high precision during the platelet test, has a low operation cost due to the configuration of a microfluidic chip and a simple system, and is capable of performing measurement in a short period of time.

[0080] The effects of the present invention are not limited to the above-described effects, and the potential effects expected by the technical features of the present invention will be clearly understood from the following description.

[0081] The above description merely illustrates the technical spirit of the present invention, and those skilled in the art can make various changes and modifications without departing from the scope of essential characteristics of the present invention.

[0082] Accordingly, the embodiments disclosed in the present invention are intended not to limit but to describe the technical spirit of the present invention, and the scope of the technical spirit of the present invention is not limited by these embodiments.

[0083] The scope of protection of the present invention must be interpreted by the accompanying claims, and it should be interpreted that all the technical spirit within a scope equivalent thereto are included in the scope of rights of the present invention.